

Ref: UHB 19-725

Freedom of Information Request

18 December 2019

By Email

Dear Sir/Madam

Thank you for your request for information under the Freedom of Information Act 2000. The Trust's response is as follows:

Please detail the number of Oncology patients treated by your Trust with the stated therapies, during the time period January 2019 to June 2019 inclusive.

| | | Total Number of Patients Treated: 257 | | | | | |
|--------------------------|--|---------------------------------------|----------------------|------------------------|---|----------------------------------|--|
| | Total Number of Patients Treated | Head & Neck Cancer | Adjuvant Melanoma | Metastatic Melanoma | Non- Small Cell Lung Cancer (NSCLC) | Renal Cell Carcinoma (RCC) | |
| Pembrolizumab (Keytruda) | 102 | 0 | 9 | 20 | 63 | 0 | |
| Nivolumab (Opdivo) | 61 | 4 | 5 | 28 | 6 | 18 | |
| Ipilimumab (Yervoy) | 8 | 0 | 0 | 7 | 0 | 1 | |
| Dabrafenib (Tafinlar) | 20 | 0 | 3 | 17 | 0 | 0 | |
| Cabozantinib (Cabometyx) | 12 | 0 | 0 | 0 | 0 | 12 | |
| Sunitinib (Sutent) | 20 | 0 | 0 | 0 | 0 | 19 | |
| Pazopanib (Votrient) | 7 | 0 | 0 | 0 | 0 | 7 | |
| Axitinib (Inlyta) | 7 | 0 | 0 | 0 | 0 | 7 | |
| Atezolizumab (Tecentriq) | 16 | 0 | 0 | 0 | 15 | 0 | |
| Sorafenib (Nexavar) | 17 | 0 | 0 | 0 | 0 | 0 | |

| Tivozanib (Fotivda) | 9 | 0 | 0 | 0 | 0 | 9 |
|------------------------|---|---|---|---|---|---|
| Lenvatinib (Lenvima) | 2 | 0 | 0 | 0 | 0 | 0 |
| Cetuximab (Erbitux) | 6 | 6 | 0 | 0 | 0 | 0 |
| Everolimus (Afinitor) | 4 | 0 | 0 | 0 | 0 | 0 |
| Vemurafenib (Zelboraf) | 1 | 0 | 0 | 1 | 0 | 0 |

Patients treated in clinical trials are not included. Where patients have been treated with a combination of two of the drugs in the table we have included them in both cells.

The number of all patients treated with the drug for any diagnosis is in the 'Total number of patients Treated' column. In the 'total number of patients treated' box at the top of the table we have provided the sum of all the treatments listed for all of the diseases specified.

This concludes our response. We trust that you find this helpful, but please do not hesitate to contact us directly if we can be of any further assistance.

If, after that, you are dissatisfied with the handling of your request, you have the right to ask for an internal review. Internal review requests should be submitted within two months of the date of receipt of the response to your original letter and should be addressed to:

Director of Corporate Governance
University Hospitals Bristol NHS Foundation Trust
Trust Headquarters
Marlborough Street
Bristol
BS1 3NU

Please remember to quote the reference number above in any future communications.

If you are not content with the outcome of the internal review, you have the right to apply directly to the Information Commissioner for a decision. The Information Commissioner can be contacted at: Information Commissioner's Office, Wycliffe House, Water Lane, Wilmslow, Cheshire, SK9 5AF

Publication

Please note that this letter and the information included/attached will be published on our website as part of the Trust's Freedom of Information Publication Log. This is because information disclosed in accordance with the Freedom of Information Act is disclosed to the public, not just to the individual making the request. We will remove any personal information (such as your name, email and so on) from any information we make public to protect your personal information.

To view the Freedom of Information Act in full please click here.

Yours sincerely

FOI Team UH Bristol NHS Foundation Trust